TY - JOUR
T1 - Circulating tumor cells
T2 - Advances in isolation and analysis, and challenges for clinical applications
AU - Harouaka, Ramdane
AU - Kang, Zhigang
AU - Zheng, Si Yang
AU - Cao, Liang
N1 - Funding Information:
We thank Jennifer Crawford for editing the manuscript. This work is directly supported by the Intramural Research Program of the US National Cancer Institute (NCI) of the National Institutes of Health (Z.K. and L.C.) and by the NCI ( R21CA161835 , DP2CA174508 , R.H. and S.Z.) in preparing the manuscript. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.
PY - 2014/2
Y1 - 2014/2
N2 - Circulating tumor cells (CTCs) are rare cancer cells released from tumors into the bloodstream that are thought to have a key role in cancer metastasis. The presence of CTCs has been associated with worse prognosis in several major cancer types, including breast, prostate and colorectal cancer. There is considerable interest in CTC research and technologies for their potential use as cancer biomarkers that may enhance cancer diagnosis and prognosis, facilitate drug development, and improve the treatment of cancer patients. This review provides an update on recent progress in CTC isolation and molecular characterization technologies. Furthermore, the review covers significant advances and limitations in the clinical applications of CTC-based assays for cancer prognosis, response to anti-cancer therapies, and exploratory studies in biomarkers predictive of sensitivity and resistance to cancer therapies.
AB - Circulating tumor cells (CTCs) are rare cancer cells released from tumors into the bloodstream that are thought to have a key role in cancer metastasis. The presence of CTCs has been associated with worse prognosis in several major cancer types, including breast, prostate and colorectal cancer. There is considerable interest in CTC research and technologies for their potential use as cancer biomarkers that may enhance cancer diagnosis and prognosis, facilitate drug development, and improve the treatment of cancer patients. This review provides an update on recent progress in CTC isolation and molecular characterization technologies. Furthermore, the review covers significant advances and limitations in the clinical applications of CTC-based assays for cancer prognosis, response to anti-cancer therapies, and exploratory studies in biomarkers predictive of sensitivity and resistance to cancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=84891880112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891880112&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2013.10.004
DO - 10.1016/j.pharmthera.2013.10.004
M3 - Review article
C2 - 24134902
AN - SCOPUS:84891880112
SN - 0163-7258
VL - 141
SP - 209
EP - 221
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
IS - 2
ER -
